source
- Elevar Therapeutics receives FDA approval for Lyrfigtu as second-line treatment for bile duct cancerThe U.S. Food and Drug Administration has approved Elevar Therapeutics' drug Lyrfigtu as a second‑line option for patients with bile duct cancer who meet specific criteria. Bile duct cancer is dia…
- STAT's The Readout LOUD podcast goes international with a Shanghai dispatch on China's biotech surgeThe Readout LOUD podcast, part of STAT's weekly biotech series, is expanding its reach beyond the United States this week. Host Jason Mast reports from Shanghai, where he examines how China's growi…